Skip to content

cottrell/mybin

Folders and files

NameName
Last commit message
Last commit date

Latest commit

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Repository files navigation

mybin

Notes, links, scripts, memories, recommendations, ghosts etc.

state:

  • did chron log
  • latex notes.tex -> notes.pdf math
  • mybin/README.me dumping ground
  • github notebooks sandbox code

shadow state:

  • Google Keep
  • misc bookmark collections in chrome
  • misc spread sheets

See here to regenerate the TOC

Managing notes, ideas, search

services and tools for business and productivity

Start with this list: https://github.com/cjbarber/ToolsOfTheTrade

Tech

hft, markets

Key value store:

Misc

Time tracking:

finance/markets/trading

Misc quant projects

Stochastic, math fin etc

Brokers or MD providers with reasonable apis

  • IB (Interactive Brokers)
  • Saxo
  • darwinex (name I can never remember)
  • deribit
  • alpaca?
  • alphavantage?
  • quantitativebrokers?

Trading, securities etc

mulitcharts info

fx is free but other feeds are through your broker or other data provider. See below for supported lists.

Regs for payment systems and retail bank-like entities (revolute):

Elicitability, Quantiles, Expectiles etc

Bregman etc

Same thing but copy pastable into "Copy All URLs for Google Chrome" app:

http://gcoe-mi.jp/temp/publish/3d079baa66570bfabd11590a3c20ff34.pdf
http://reports-archive.adm.cs.cmu.edu/anon/2001/CMU-CS-01-109R.pdf
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.135.1357&rep=rep1&type=pdf
https://github.com/RagibZaman/mathematical-optimisation/blob/master/bregman_optimisation/bregman_optimisation.pdf
https://arxiv.org/abs/1004.3814
https://github.com/RagibZaman/mathematical-optimisation/tree/master/bregman_optimisation/BregmanLR_demo
https://people.ok.ubc.ca/bauschke/Research/07.pdf
http://www.cs.jhu.edu/~ayuille/courses/Stat238-Winter12/Pietra.pdf
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.33.1529&rep=rep1&type=pdf
https://www.aclweb.org/anthology/J96-1002.pdf
https://arxiv.org/abs/1905.11545
https://arxiv.org/pdf/1808.08271.pdf
https://www.inference.vc/grosses-challenge/
https://github.com/fhuszar/thesis/tree/master/submitted

causal inference, causal graphs, probabilistic programming

NOTE on D-separation: X is d-separated from Y given Z (in G) iff all undirected paths between X and Y are inactive relative to Z. An undirected path is inactive relative to Z iff ANY (at least one) node on the path is inactive relative to Z. A node is inactive relative to Z iff a) it is a non-collider in Z OR b) is a collider not in Z and has no descendents in Z

Strong ignorability says that, conditional on the confounders, the assigned causes are independent of the potential outcomes,

Possibly good toolkits

Other tools and articles

people

clustering, record linkage etc

backtesting/trading tools

  • pyalgotrade
  • zipline
  • pyfolio
  • backtrader

Top candidates for generic analytics and viz

See this list https://wiki.nikitavoloboev.xyz/data-science/data-processing

Decentralized data networks?

Look at these 2022

platforms

  • snowflake
  • lakehouse
  • azure ml
  • qwak

Dataframes, data ingestion

Research:

Analytics/Viz:

vega observable related

Other lists

js dataframes

2021-12: keep messing around with observable as it allows state caching notebook style. See here for "recommended" libraries https://observablehq.com/@observablehq/recommended-libraries

2021-05: If there is some fast serializing to danfo it looks good. Look for arrow danfo interactions. See arquero.

Viz for larger datasets and graphs

Other

Data exploration

Actual data & viz

Markets

Non-Markets

Tech env

task queues

decentralized finance whatever that means

prediction markets

Interesting protocols

PoST

  • spacemesh
  • definity
  • phala
  • nodle

decentralized data, research, distributed fs, syncing, data versioning etc

Current top of the list

CALM and logical monotonicity:

From Alaric:

paxos notes https://martinfowler.com/articles/patterns-of-distributed-systems/paxos.html

Other notes

Deterministic DB

Betting, smart contracts etc

RPC/caching/dataframe Frameworks like dask and spark

bitemporal stuff

Search for bitemporal streaming or some such thing.

Sort of related: "A Broadcast-Only Communication Model Based on Replicated Append-Only Logs" https://ccronline.sigcomm.org/wp-content/uploads/2019/05/acmdl19-295.pdf

Time Series DB analytics etc

Graph DB

dedupe archival db related

Note there is something called "upsert" in deltalake

Immutable db etc

stream processing etc

merkle tree

merkle db

workflow, dag stuff etc

data pipelines, streaming etc

want kafka but hate kafka

data quality

Maybe these:

Maybe not these:

hardware

privacy, security etc

links uncategorized

maths, probability, stochastic etc

SGD, Langevin, batch-size etc

Stochastic Duality

Interacting Particle Systems (and duality)

feature stores

ml, machine learning, rl, reinforcement learning

dimensional analysis

sequence learning related

simulators

factorization machines

distributed algos

nearest neighbor

Normalizing Flows and Density Estimation

mixture density network links

lstm/rnn examples

hyper param opt

other lists

ml/rl environments

GP

CV exploratory approaches

sum product

custom objectives

hardware

tax, spending, fiscal, gov etc

APIs

travel

engineering

maybe useful libs to watch

historical

browser

  • beaker
  • brave
  • epic
  • vivaldi
  • tor

web

coursera

DB and analytics

Time-series 2019

Misc 2021

object stores

  • Minio
  • GlusterFS
  • Cephs

messaging

data discovery and meta data etc

semantic web and things I tend to ignore

Semantic web search engines?

articles and data

language data (dictionaries etc)

todo

GPG etc

gpg --gen-key
gpg --list-secret-keys --keyid-format LONG
gpg --armor --export <id>

drone

Concurrency

Monoclonal Antibodies

A very quick read and summary through some links.

Quick view from Forbes: https://www.forbes.com/sites/williamhaseltine/2020/04/23/promising-new-drugs-to-treat-and-prevent-covid-19/#44c1d0b145bf

How soon will drugs be available? My guess, within three to four months for the first approvals.

It may take several weeks to demonstrate effectiveness in animals. Human safety studies can be done with no more than 30 people in about a month. These drugs are generally known to be safe though more testing for safety will be required. Tests of the drugs’ effect in reducing the viral load in infected patients should take no longer than a month. Most time consuming will be large scale manufacturing of the drugs, once approved.

Mostly focused on details of production. Figure 3 for production/approval pipeline ... https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-019-0592-z Two methods:

  • phage display, wherein diverse exogenous genes are incorporated into filamentous bacteriophages to compose a library. The library proteins are then presented on the phage surface as fusions with a phage coat protein, allowing the selection of specific binders and affinity characteristics.
  • Transgenic animals represent another technology for obtaining fully human mAbs.

The recent development of bispecific antibodies offers attractive new opportunities for the design of novel protein therapeutics. A bispecific antibody can be generated by utilizing protein engineering techniques to link two antigen binding domains (such as Fabs or scFvs), allowing a single antibody to simultaneously bind different antigens.

The mAb market enjoys a healthy pipeline and is expected to grow at an increasing pace, with a current valuation of $115.2 billion in 2018 [44]. Despite this high growth potential, new companies are unlikely to take over large shares of the market, which is currently dominated by seven companies:

  • Genentech (30.8%)
  • Abbvie (20.0%)
  • Johnson & Johnson (13.6%)
  • Bristol-Myers Squibb (6.5%)
  • Merck Sharp & Dohme (5.6%)
  • Novartis (5.5%)
  • Amgen (4.9%)
  • with other companies comprising the remaining 13% [44].

This is good for market and timelines, probably longer than would happen now: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622599/

Based on a review of historical success and turnover rates (i.e., the length of time required for a product to move from one stage of development to the next) of biopharmaceutical product development candidates, ∼26% of the monoclonal antibody products entering Phase 2 human clinical trials in recent years will ultimately achieve market approval with an average time from the start of Phase 2 clinical trials to approval of ∼ seven years.5-7

Another one mostly on details of production: https://www.intechopen.com/books/fermentation-processes/production-processes-for-monoclonal-antibodies

In general, a process of commercial production of mAb begins with the generation of an mAb by immunizing an animal or by molecular biology methods involving the identification and optimization of the coding DNA sequence and the construction and identification of a stable high-producing clone. Improvements in cultivation are similar to those applied in other bioproducts that rely on culturing microorganisms or cells, requiring the development of a well-designed culturing process comprising the full range of control and associated operations that will support technical evaluations

This one has some timelineshttps://www.researchgate.net/publication/23656557_Monoclonal_Antibodies_as_Innovative_Therapeutics/figures?lo=1

This one is just a snippet but apparently short half life is an issue?

10.3 Drawbacks of Monoclonal Antibodies Monoclonal antibodies (mAbs) are extensively used in the areas of diagnostics and healthcare. Despite their extensive use, mAbs present several disadvantages, namely, they are very expensive and difficult to produce. Additionally, their large molecular size (150 kDa) limits their tissue and tumor penetration, thus limiting their biodistribution and efficacy. Moreover, they can also induce immune reactions, which further limits their long-term application. Lastly, mAbs have a half-life of several days, which leads to high background signals when used for molecular imaging.

Other links:

Alternatives to medium

See here

Automated Theorem Proving

stack 2020

  • replace argh with typer?

voting

fast distance matrix calculations

Also see:

About

misc scripts and notes

Resources

Stars

Watchers

Forks

Releases

No releases published

Packages

No packages published

Languages